558 related articles for article (PubMed ID: 19736814)
1. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
[TBL] [Abstract][Full Text] [Related]
2. Can tumor necrosis factor inhibitors be safely used in pregnancy?
Ali YM; Kuriya B; Orozco C; Cush JJ; Keystone EC
J Rheumatol; 2010 Jan; 37(1):9-17. PubMed ID: 20008917
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Thompson AE; Rieder SW; Pope JE
Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
Skomsvoll JF; Wallenius M; Koksvik HS; Rødevand E; Salvesen KA; Spigset O; Kvien TK
Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
[TBL] [Abstract][Full Text] [Related]
5. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach.
Winterhalter S; Niehues T
Klin Padiatr; 2008; 220(6):342-7. PubMed ID: 18949668
[TBL] [Abstract][Full Text] [Related]
6. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis and reproduction.
Golding A; Haque UJ; Giles JT
Rheum Dis Clin North Am; 2007 May; 33(2):319-43, vi-vii. PubMed ID: 17499710
[TBL] [Abstract][Full Text] [Related]
8. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of juvenile idiopathic arthritis].
Horneff G; Augustin S
Med Monatsschr Pharm; 2008 Sep; 31(9):326-36; quiz 337-8. PubMed ID: 18831464
[TBL] [Abstract][Full Text] [Related]
11. Malignancy and biologic therapy in rheumatoid arthritis.
Askling J; Bongartz T
Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide.
Massardo L; Suárez-Almazor ME; Cardiel MH; Nava A; Levy RA; Laurindo I; Soriano ER; Acevedo-Vázquez E; Millán A; Pineda-Villaseñor C; Galarza-Maldonado C; Caballero-Uribe CV; Espinosa-Morales R; Pons-Estel BA
J Clin Rheumatol; 2009 Jun; 15(4):203-10. PubMed ID: 19502907
[TBL] [Abstract][Full Text] [Related]
15. Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy?
Brar A; Hiebert T; El-Gabalawy H
Nat Clin Pract Rheumatol; 2007 Mar; 3(3):120-1. PubMed ID: 17334334
[No Abstract] [Full Text] [Related]
16. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A; Greenberg JD
Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
[TBL] [Abstract][Full Text] [Related]
17. A safety assessment of tumor necrosis factor antagonists during pregnancy.
Osting VC; Carter JD
Expert Opin Drug Saf; 2010 May; 9(3):421-9. PubMed ID: 20367495
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.
Cacciapaglia F; Navarini L; Menna P; Salvatorelli E; Minotti G; Afeltra A
Autoimmun Rev; 2011 Aug; 10(10):631-5. PubMed ID: 21539939
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
[No Abstract] [Full Text] [Related]
20. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
Pieringer H; Pichler M
QJM; 2011 Jan; 104(1):13-26. PubMed ID: 21068083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
